SubHero Banner

Remodulin® (treprostinil) – New formulation approval

July 31, 2018 - United Therapeutics announced the FDA approval for the use of Remodulin (treprostinil) injection in Medtronics’ Implantable System for Remodulin (ISR) for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise, and to diminish the rate of clinical deterioration in patients with PAH who require transition from Flolan® (epoprostenol).

Download PDF